4 Results for "

Ulixertinib

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Ulixertinib" in MCE Product Catalog:

52
52 Cited Publications
Cat. No.: HY-15816
CAS No.: 869886-67-9
Purity:  99.95%
Synonyms: BVD-523; VRT752271
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-15816A
CAS No.: 1956366-10-1
Purity:  99.89%
Synonyms: BVD-523 hydrochloride; VRT752271 hydrochloride
Target:  

ERK

Research Areas:  

Cancer

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
Cat. No.: HY-15816R
CAS No.: 869886-67-9
Synonyms: BVD-523 (Standard); VRT752271 (Standard)
Target:  

ERK Reference Standards

Research Areas:  

Cancer

Ulixertinib (Standard) is the analytical standard of Ulixertinib. This product is intended for research and analytical applications. Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .
loading...
    loading...
Cat. No.: HY-184412
Target:  

SHP2 Apoptosis p38 MAPK

Research Areas:  

Cancer

SDUY104 is an orally active amide-based allosteric inhibitor of SHP2 with an IC50 of 140 nM. SDUY104 impairs KRAS-driven pancreatic cancer cell proliferation via cell-cycle arrest and apoptosis. SDUY104 suppresses MAPK signaling and triggers compensatory PI3K-AKT activation. SDUY104 can be used for KRAS-mutant pancreatic cancer research .
loading...
    loading...